Tenaya Therapeutics, Inc.
General ticker "TNYA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $130.9M (TTM average)
Tenaya Therapeutics, Inc. follows the US Stock Market performance with the rate: 35.9%.
Estimated limits based on current volatility of 3.0%: low 0.74$, high 0.79$
Factors to consider:
- Total employees count: 97 (-30.7%) as of 2024
- Top business risk factors: Operational and conduct risks, High risk of business failure, Early stage company risks, Development risks, Product development delays
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.54$, 1.80$]
- 2026-12-31 to 2027-12-31 estimated range: [0.63$, 1.96$]
Financial Metrics affecting the TNYA estimates:
- Positive: with PPE of -1.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -62.62 <= 0.07
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 83.90 > 64.25
- Positive: Investing cash flow per share per price, % of 51.45 > -0.65
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term TNYA quotes
Long-term TNYA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $131.19MM | $115.95MM | $93.33MM |
| Operating Income | $-131.19MM | $-115.95MM | $-93.33MM |
| Non-Operating Income | $7.11MM | $4.82MM | $2.73MM |
| R&D Expense | $98.04MM | $86.74MM | $68.61MM |
| Income(Loss) | $-124.08MM | $-111.13MM | $-90.60MM |
| Profit(Loss)* | $-124.08MM | $-111.13MM | $-90.60MM |
| Stockholders Equity | $139.42MM | $92.85MM | $123.27MM |
| Assets | $170.51MM | $119.94MM | $146.92MM |
| Operating Cash Flow | $-102.07MM | $-90.50MM | $-68.26MM |
| Capital expenditure | $1.24MM | $1.02MM | $0.62MM |
| Investing Cash Flow | $48.72MM | $1.13MM | $56.08MM |
| Financing Cash Flow | $4.05MM | $47.75MM | $108.41MM |
| Earnings Per Share** | $-1.68 | $-1.31 | $-0.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.